Formulation and Evaluation of Organogels Containing Hyaluronan Microparticles for Topical Delivery of Caffeine
- 103 Downloads
Cellulite is a dermal disorder including the extracellular matrix, the lymphatic and microcirculatory systems and the adipose tissue. Caffeine is used as the active moiety depending its preventive effect on localization of fat in the cellular structure. Hyaluronic acid (hyaluronan-HA) is a natural constituent of skin that generates formation and poliferation of new cells having a remarkable moisturizing ability. The aim of this study is to formulate HA microparticles loaded with caffeine via spray-drying method. Resulting microparticle formulations (33.97 ± 0.3 μm, span < 2, 88.56 ± 0.42% encapsulation efficiency) were distributed in lecithin organogels to maintain the proper viscosity for topical application. Following the characterization and cell culture studies, in vitro drug release and ex vivo permeation studies were performed. The accumulated amount of caffeine was twice higher than the aqueous solution for the microparticle-loaded organogels at 24 h (8262,673 μg/cm2versus 4676,691 μg/cm2). It was related to the sustained behaviour of caffeine release from the microparticles. As a result, lecithin organogel containing HA-encapsulated microparticles could be considered as suitable candidate formulations for efficient topical drug delivery system of caffeine. In addition to that, synergistic effect of this combination appears as a promising approach for long-acting treatment of cellulite.
KEY WORDScaffeine hyaluronan microparticles organogel cellulite skin permeation
This study was supported by the Research Foundation of Ege University (Grant Number 12/ECZ/029). The authors are grateful to Prof. Hande Gürer Orhan from Ege University, Faculty of Pharmacy, Department of Toxicology for conducting cell culture studies and Ege University, Faculty of Pharmacy, Pharmaceutical Sciences Research Centre (FABAL) for equipmental support in UPLC analysis. The authors would also like to thank TUBITAK for purchasing of the spray dryer under the project number 111S183.
Compliance with Ethical Standards
Wistar Albino rats used for the study were approved by the Local Animal Ethical Committee.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 4.B. Sandrine, M. B. Alexandrine, P. Jocelyne, V.J. Pierre, and S. Briançon. Caffeine Microspheres –An Attractive Carrier To Achieve Optimum Skin Penetration. in Cosmetic Science Conference −2009 Proceedings. 2013.Google Scholar
- 6.Rodrigues F, Alves AC, Nunes C, Sarmento B, Amaral MH, Reis S, et al. Permeation of topically applied caffeine from a food by-product in cosmetic formulations: is nanoscale in vitro approach an option? Int J Pharm. 2016;513(1-2):496–503. https://doi.org/10.1016/j.ijpharm.2016.09.059.CrossRefGoogle Scholar
- 8.Swatschek D, Schatton W, Muller W, Kreuter J. Microparticles derived from marine sponge collagen (SCMPs): preparation, characterization and suitability for dermal delivery of all-trans retinol. Eur J Pharm Biopharm. 2002;54(2):125–33. https://doi.org/10.1016/S0939-6411(02)00046-2.CrossRefGoogle Scholar
- 10.Eroglu I, Gokce EH, Tsapis N, Tanriverdi ST, Gokce G, Fattal E, et al. Evaluation of characteristics and in vitro antioxidant properties of RSV loaded hyaluronic acid-DPPC microparticles as a wound healing system. Colloids Surf B Biointerfaces. 2015;126:50–7. https://doi.org/10.1016/j.colsurfb.2014.12.006.CrossRefGoogle Scholar
- 12.Gokce EH, Tanrıverdi ST, Eroglu I, Tsapis N, Gokce G, Tekmen I, et al. Wound healing effects of collagen-laminin dermal matrix impregnated with resveratrol loaded hyaluronic acid-DPPC microparticles in diabetic rats. Eur J Pharm Biopharm. 2017;119:17–27. https://doi.org/10.1016/j.ejpb.2017.04.027.CrossRefGoogle Scholar
- 13.Gomez-Gaete C, Tsapis N, Silva L, Bourgaux C, Besnard M, Bochot A, et al. Supramolecular organization and release properties of phospholipid-hyaluronan microparticles encapsulating dexamethasone. Eur J Pharm Biopharm. 2008;70(1):116–26. https://doi.org/10.1016/j.ejpb.2008.04.013.CrossRefGoogle Scholar
- 14.Gomez Gaete C, Tsapis N, Silva L, Bourgaux C, Fattal E. Morphology, structure and supramolecular organization of hybrid 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine-hyaluronic acid microparticles prepared by spray drying. Eur J Pharm Sci. 2008;34(1):12–21. https://doi.org/10.1016/j.ejps.2008.02.003.CrossRefGoogle Scholar
- 18.Shona Pek Y, Kurisawa M, Gao S, Chung JE, Ying JY. The development of a nano- apatite reinforced crosslinked hyaluronic acid–tyramine composite as an injectable bone cement. Biomaterials. 2009;30(5):822–8. https://doi.org/10.1016/j.biomaterials.2008.10.053.CrossRefGoogle Scholar
- 20.Cheolbyong C, Deuk Yong L, Jin-Tae K, Mi-Kyung K, Young-Zu K, Seok-Soon K. Effect of molecular weight of hyaluronic acid (HA) on viscoelasticity and particle texturing feel of HA dermal biphasic fillers. Biomater Res. 2016;20(24).Google Scholar
- 24.Surjyanarayan M, Snigdha SM, Krutika KS. Lecithin stabilized Organogel: design and development for topical application of Clobetasol propionate. Int J PharmTech Res. 2010;2:1133–8.Google Scholar
- 27.Eroğlu H, Haidar MK, Nemutlu E, Öztürk Ş, Bayram C, Ulubayram K, et al. Dual release behavior of atorvastatin and alpha-lipoic acid from PLGA microspheres for the combination therapy in peripheral nerve injury. J Drug Delivery Sci Technol. 2017;39:455–66. https://doi.org/10.1016/j.jddst.2017.04.028.CrossRefGoogle Scholar
- 28.ICH Expert Working Group. Stability testing of new drug substances and Products Q1A (R2). 2003. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2__Guideline.pdf.
- 29.Gowda DV, Khan MS, Nagendra R. Spray dried indapamide microparticles for controlled release– a novel approach. Int J Pharm Bio Sci. 2010;1:459–66.Google Scholar
- 30.Zhang P, Chen L, Gu W, Xu Z, Gao Y, Li Y. In vitro and in vivo evaluation of donepezil-sustained release microparticles for the treatment of Alzheimer's disease. Biomaterials. 2007;28(10):1882–8. https://doi.org/10.1016/j.biomaterials.2006.12.016.CrossRefGoogle Scholar
- 31.Rossi T, Iannuccelli V, Coppi G, Bruni E, Baggio G. Role of the pharmaceutical excipients in the tamoxifen activity on MCF-7 and vero cell cultures. Anticancer Res. 2009;29(11):4529–33.Google Scholar
- 33.Tamura T, Ichikawa M. Effect of lecithin on Organogel formation of 12-Hydroxystearic acid. JAOCS. 1997;74(5).Google Scholar
- 40.Rencber S, Karavana SY, Senyigit ZA, Erac B, Limoncu MH, Baloglu E. Mucoadhesive a priori gel formulation for vaginal delivery of clotrimazole: formulation, preparation, and in vitro/in vivo evaluation. Pharm Dev Technol. 2017;22(4):551–61. https://doi.org/10.3109/10837450.2016.1163385.CrossRefGoogle Scholar
- 41.Aksungur P, Demirbilek M, Denkbas EB, Vandervoort J, Ludwig A, Unlu N. Development and characterization of cyclosporine a loaded nanoparticles for ocular drug delivery: cellular toxicity, uptake, and kinetic studies. J Control Release. 2011;151(3):286–94. https://doi.org/10.1016/j.jconrel.2011.01.010.CrossRefGoogle Scholar